Search / Trial NCT00001803

Von Hippel-Lindau Disease Genetic Epidemiology Study

Launched by NATIONAL CANCER INSTITUTE (NCI) · Nov 3, 1999

Trial Information

Current as of December 26, 2024

Terminated

Keywords

Gene Environment Interaction Kidney Cancer Vhl Genetic Epidemiology

ClinConnect Summary

The Von Hippel-Lindau (VHL) Disease Genetic Epidemiology Study is a family-based case-control study to be conducted by the National Cancer Institute. The study subjects are 603 individuals who were determined to belong to families with VHL disease confirmed through screening under NIH protocol #89-C-0086 between 1988 and 1998. There are 293 patient volunteers with VHL disease and 310 volunteer patients free of VHL disease, most of whom have already had genetic testing for mutations in the VHL gene. Adults as well as children aged 13 - 17 will be included. All subjects will give informed con...

Gender

ALL

Eligibility criteria

  • * INCLUSION CRITERIA:
  • Eligible patient volunteers are those who:
  • 1. have been enrolled in protocol 89-C-0086;
  • 2. are a member of a family in which at least one person has been diagnosed with VHL at NIH; and
  • 3. are at least 13 years of age.
  • Patient volunteers seen under protocol 89-C-0086 who have been diagnosed with VHL, are at risk of VHL, or are unaffected are all eligible for study.
  • Additional families screened throughout the field period and meeting all eligibility criteria will also be able to participate.

Trial Officials

Neil E Caporaso, M.D.

Principal Investigator

National Cancer Institute (NCI)

About National Cancer Institute (Nci)

The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials